{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:03:40Z","timestamp":1791655420280,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.medcli.2019.01.010","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T03:29:45Z","timestamp":1552015785000},"page":"502-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases"],"prefix":"10.1016","volume":"152","author":[{"given":"Beatriz P.","family":"Braga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2019.01.010_bib0275","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2019.01.010_bib0280","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/649868","article-title":"Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population","volume":"50","author":"Ponce","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2334-4-42","article-title":"Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention","volume":"4","author":"Sowden","year":"2004","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0290","doi-asserted-by":"crossref","first-page":"e0139144","DOI":"10.1371\/journal.pone.0139144","article-title":"Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death","volume":"10","author":"Chen","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.medcli.2019.01.010_bib0295","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/acr.20435","article-title":"Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series","volume":"63","author":"Kermani","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2019.01.010_bib0300","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13054-018-2221-8","article-title":"Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years","volume":"22","author":"Schmidt","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.medcli.2019.01.010_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2014.11.025","article-title":"Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers","volume":"21","author":"Esteves","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2019.01.010_bib0310","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study","volume":"36","author":"De Castro","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.medcli.2019.01.010_bib0315","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0320","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1086\/342338","article-title":"Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study","volume":"35","author":"Zahar","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.medcli.2019.01.010_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.medcli.2019.01.010_bib0335","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12651","article-title":"The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review","volume":"19","author":"Messiaen","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0340","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s10067-013-2293-4","article-title":"Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?","volume":"32","author":"Besada","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0345","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/rheumatology\/keq314","article-title":"Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome","volume":"50","author":"Mekinian","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2019.01.010_bib0350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/03009742.2011.630328","article-title":"High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy","volume":"41","author":"Fritzsche","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0355","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"A survey of rheumatologists\u2019 practice for prescribing Pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0360","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2019.01.010_bib0365","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","article-title":"Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review","volume":"26","author":"Falagas","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0370","first-page":"490","article-title":"Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases","volume":"36","author":"Baulier","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0375","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/2325957416667486","article-title":"Prescription of Pneumocystis jiroveci pneumonia prophylaxis in HIV-infected patients","volume":"15","author":"Lin","year":"2016","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.medcli.2019.01.010_bib0380","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medcli.2019.01.010_bib0385","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005590.pub3","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2019.01.010_bib0390","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3899\/jrheum.091426","article-title":"Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?","volume":"37","author":"Stamp","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0395","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim\u2013sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0400","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0b013e31817a7e30","article-title":"Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature","volume":"14","author":"Gupta","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0405","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/ar2826","article-title":"Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?","volume":"11","author":"Moosig","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.medcli.2019.01.010_bib0410","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2019.01.010_bib0415","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10067-018-4155-6","article-title":"Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis","volume":"37","author":"Metraiah","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0420","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0425","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.rce.2014.07.011","article-title":"Diffuse alveolar hemorrhage associated with Henoch\u2013Schonlein purpura and Pneumocystis jirovecii infection: a case report","volume":"215","author":"Hernandez Roca","year":"2015","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.medcli.2019.01.010_bib0430","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases","volume":"21","author":"Godeau","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0435","first-page":"170","article-title":"Pneumocystis carinii pneumonia following corticosteroid therapy for giant cell arteritis","volume":"90","author":"Crayton","year":"1991","journal-title":"Wis Med J"},{"key":"10.1016\/j.medcli.2019.01.010_bib0440","first-page":"S122","article-title":"Risk factors for Pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study","volume":"33","author":"Berger","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0445","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.23822","article-title":"When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases","volume":"59","author":"Suryaprasad","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2019.01.010_bib0450","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0961203317703494","article-title":"Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse","volume":"26","author":"Kapoor","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.medcli.2019.01.010_bib0455","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2019.01.010_bib0460","article-title":"Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: a nested case\u2013control study","author":"Nunokawa","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.medcli.2019.01.010_bib0465","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2019.01.010_bib0470","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","article-title":"Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0475","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-018-4157-4","article-title":"Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum","author":"Shimada","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0480","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole","volume":"24","author":"Yukawa","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0485","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1756-185X.13255","article-title":"Opportunistic infections in patients with idiopathic inflammatory myopathies","volume":"21","author":"Redondo-Benito","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0490","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005792-200303000-00002","article-title":"Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy","volume":"82","author":"Viguier","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2019.01.010_bib0495","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/archinte.1997.00440340145015","article-title":"Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis","volume":"157","author":"Bachelez","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.medcli.2019.01.010_bib0500","doi-asserted-by":"crossref","first-page":"e8846","DOI":"10.1097\/MD.0000000000008846","article-title":"Severe infections in sarcoidosis: incidence, predictors and long-term outcome in a cohort of 585 patients","volume":"96","author":"Dureault","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2019.01.010_bib0505","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2133.1999.03052.x","article-title":"Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases","volume":"141","author":"Raychaudhuri","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0510","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0515","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11926-014-0445-4","article-title":"Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis","volume":"16","author":"Grubbs","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.medcli.2019.01.010_bib0520","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2017.02.010","article-title":"Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping","volume":"57","author":"Li","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.medcli.2019.01.010_bib0525","doi-asserted-by":"crossref","first-page":"e28570","DOI":"10.1371\/journal.pone.0028570","article-title":"Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200cells\/microL and virologic suppression: a systematic review","volume":"6","author":"Costiniuk","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.medcli.2019.01.010_bib0530","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.medcli.2019.01.010_bib0535","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/s10165-012-0625-x","article-title":"Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim\u2013sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases","volume":"23","author":"Maezawa","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.medcli.2019.01.010_bib0540","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/acr.21857","article-title":"Recent-onset systemic lupus erythematosus complicated by acute respiratory failure","volume":"65","author":"Demoruelle","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319300569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319300569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T22:04:05Z","timestamp":1559772245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319300569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0025775319300569"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.01.010","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}